Sign in Subscribe

Remdesivir

Early results from COVID-19 drug trial boost optimism

Early results from COVID-19 drug trial boost optimism

Dr. Anthony Fauci, the top United States infectious disease official, has expressed confidence in biotechnology company Gilead Sciences Inc.’s experimental antiviral drug remdesivir being the “standard of care” for COVID-19. This comes after preliminary results from a key clinical trial were shown on Wednesday, April 29 that patients given

68% of severe COVID-19 cases improved with Gilead Sciences’ remdesivir drug

68% of severe COVID-19 cases improved with Gilead Sciences’ remdesivir drug

Remdesivir, a drug created by Gilead Sciences (GILD), has been tested on individuals suffering from severe cases of COVID-19. The drug was initially created to treat Ebola patients and was tested in Eastern Congo. While it ultimately proved ineffective for treating Ebola, remdesivir was proven to be safe. This fact